Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Pompe disease by blood acid alpha-glucosidase assay and acid alpha-glucosidase gene sequencing,~2. Age: 18+ years at enrollment,~3. Receiving ERT at standard dose (20 mg/kg every 2 weeks) for at least 52 weeks,~4. Subjects are capable of giving written consent.~Exclusion Criteria:~1. Continuous invasive ventilation (via tracheostomy or endotracheal tube)~2. Clinically relevant illness within two weeks of enrollment including fever \> 38.2 C, vomiting more than once in 24 hours, seizure, or other symptom deemed contraindicative to new therapy.~3. Chronic heart disease (Myocardial infarction, arrythmia, cardiomyopathy)~4. Tachycardia~5. History of seizure disorder~6. Hyperthyroidism~7. Pheochromocytoma~8. Pregnancy~9. History of diabetes~10. History of hypersensitivity to beta 2-agonist drugs such as albuterol, levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline, salmeterol (Serevent),~11. Patients on a non-standard schedule for ERT; for example, weekly infusions as opposed to infusions every two weeks.~12. Treatment for asthma in the previous 12 months.~13. The use of the following concommitant meds is prohibited during the study:~    * diuretics (water pill);~   * digoxin (digitalis, Lanoxin);~   * beta-blockers such as atenolol (Tenormin), metoprolol (Lopressor), and propranolol (Inderal);~   * tricyclic antidepressants such as amitriptyline (Elavil, Etrafon), doxepin (Sinequan), imipramine (Janimine, Tofranil), and nortriptyline (Pamelor);~   * Monoamine oxidase inhibitors such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate); or~   * other bronchodilators such as albuterol, levalbuterol (Xopenex), bitolterol (Tornalate), pirbuterol (Maxair), terbutaline (Brethine, Bricanyl), salmeterol (Serevent), isoetherine (Bronkometer), metaproterenol (Alupent, Metaprel), or isoproterenol (Isuprel Mistometer).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clenbuterol (Type: EXPERIMENTAL): Initially, 40 mcg each morning for one week. Then, increase to 40 mcg BID for the next 5 weeks. If tolerated, will increase to 80 mcg in the morning and 40 mcg in the evening for one week. Then, last dose increase will be 80 mcg BID until week 52.
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Initially, one capsule each morning for one week. Then, increase to one capsule BID for the next 5 weeks. If tolerated, will increase to two capsules in the morning and one capsule in the evening for one week. Then, last dose increase will be two capsules BID until week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete